Hypertension
Conditions
Interventions
Losartan / HCTZ group
Sponsors
Kyoto University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1) Patients with hypertension, who have been previously treated with monotherapy of a standard-dose of an ARB for more than 2 months, however, whose blood pressure has not been adequately controlled (systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90mmHg) 2) Patients with CKD of stage I - IV 3) Men and women aged 20 years or older 4) Outpatients 5) Patients who fully understand the study procedures explained to them using explanatory notes and have given written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1) Patients with uncontrolled hypertension (DBP >= 110mmHg) 2) Patients with malignant hypertension 3) Patients with uncontrolled diabetes (HbA1c >= 8.0%) and patients under insulin treatment 4) Patients who have stroke, AMI and/or critical vascular complications that required hospitalization within 6 months prior to the intervention 5) Patients with liver dysfunction [GPT(ALT) over three times the normal value] 6) Patients with critical renal failure (serum creatinine >= 3.0 mg/dL) 7) Patients with a previous history of gout attack or uncontrolled hyperuricemia (UA >= 9.0mg/dL) 8) Pregnant or breast feeding female patients, including one trying to conceive pregnancy during the planned study period 9) Patients with uncontrolled arrhythmia 10) Patients with cardiac insufficiency (NYHA grade III or IV) 11) Patients with a history of hypersensitivity to ingredients of losartan 12) Patients with a history of hypersensitivity to thiazide or thiazide-like diuretics 13) Patients who are considered not eligible for the study by the attending doctor due to medical reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change and % change in blood pressure after 3 months of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| - Change and % change in blood pressure after 1 and 6 months of treatment - Change and % change in eGFR, urinary albumin excretion, serum uric acid, BNP, urinary 8OHdG and urinary Ngal after 3 and 6 months of treatment | — |
Countries
Japan
Contacts
Public ContactHideki Yokoi
Kyoto University Hospital Department of Medicine and Clinical Science
Outcome results
None listed